Jeffrey C. Mocny, PhD, of Abzena, and Anna McMahon, MS, of Cellares, discuss how biopharmaceutical risk-based standards accelerate innovation and speed-to-market by leveraging data for better patient ...

Merck’s Sanat Chattopadhyay called for stronger leadership, data-driven oversight, and shared accountability to raise pharmaceutical quality standards. Susan J. Schniepp, Distinguished Fellow, ...

Orexin neuron loss drives narcolepsy type 1’s multisymptom phenotype, and historical management has been symptom-by-symptom rather than deficit-correcting, leaving underlying biology untreated. Orexin ...

FDA authorized mFlusiva for adults 50–65 and ≥65, contingent on an additional confirmatory trial in older adults, with commercial availability targeted for the 2026–2027 flu season. A large outcomes ...

Kent Malmros is senior director of training at Veeva Systems. He has spent the majority of his career delivering technology-enabled training solutions to life-sciences companies and has held ...

PharmTech spoke with Dr. Hui-Yin (Harry) Li, president and CEO of Wilmington PharmaTech, about steps that should be taken to build a productive relationship between sponsor and contract organizations.

OSTP's July 2026 report to Trump diagnoses U.S. science slowdown and pushes deregulation, new funding models, reshoring, and AI-driven "Genesis Mission." Much of the report is broad science policy: ...

AI tools have arrived, but organizational readiness, data governance, and regulatory gaps now limit real-world impact. Six months after industry experts laid out their predictions for 2026, many of ...

Cheryl Barton, a contributing writer for PharmTech Europe, highlights how European biotechs are using AI-driven target discovery to push respiratory treatment beyond broad immunosuppression toward ...

Across development, manufacturing, quality, and outsourcing, the pharma industry is being asked to scale complexity without sacrificing control. Pharmaceutical manufacturing is entering a phase ...

Modernizing infrastructures, record drug approvals, and harmonization were all positive regulatory advancements in July 2026. This month in pharmaceutical regulations, in the United States, the FDA ...